Mechanisms of YY1 Inhibition of Cardiac Hypertrophy
YY1抑制心肌肥厚的机制
基本信息
- 批准号:7267183
- 负责人:
- 金额:$ 12.18万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-04-13 至 2012-03-31
- 项目状态:已结题
- 来源:
- 关键词:Adrenergic AgentsAgonistAnimalsBindingBiological ModelsCardiac MyocytesCatecholaminesCause of DeathCell NucleusClassConditionDataDevelopmentFrequenciesGene ExpressionGenesGoalsHeartHeart HypertrophyHeart failureHistonesHypertrophyMedicalMolecularMusMuscleNeonatalNuclear ExportPathologicProtein IsoformsPumpSignal TransductionStimulusTranscriptional ActivationTransgenic OrganismsUnited StatesUp-RegulationYY1 Transcription Factoradrenergiccardiovascular disorder preventionchromatin immunoprecipitationdisabilityfetalheart functionimplantationin vivo Modelinhibitor/antagonistmouse modelneonatepreventpromoterresponsetranscription factor
项目摘要
DESCRIPTION (provided by applicant): Heart failure is the most expensive medical problem in the United States, and a major cause of death and disability. Although pharmacological inhibitors targeted to the treatment of heart failure are therapeutically beneficial, heart failure is still increasing in frequency, and additional targets are needed. Our long term goal is to define the molecular mechanism(s) by which the transcription factor YY1 protects against pathologic cardiac hypertrophy and to provide valuable targets for the prevention of cardiac disease. YY1 is an ubiquitous transcription factor that regulates expression of multiple genes. YY1 has been shown to be mostly a represser of muscle genes. We have strong preliminary data showing that YY1 prevents the cellular changes that accompany cardiac hypertrophy. YY1 prevents up-regulation of the fetal isoforms of gene expression in response to alpha and beta adrenergic stimulation by binding to and retaining in the nucleus class II histone deacetylases (HDACs). The goals of this application are to: (Aim I) identify the mechanism by which YY1 prevents HDACs 4 and 5 nuclear export in response to various hypertrophic agonists; (Aim II) analyze the interaction of YY1 with fetal gene promoters in response to various hypertrophic stimuli (Aim III) characterize the effect of YY1 over-expression in an in vivo model system of pathological cardiac hypertrophy. Aim I will be achieved by analyzing YY1-HDAC interaction domains; constructs containing the interaction domains will be transfected into neonate cardiac myocytes and gene expression, cellular hypertrophy and HDACs 4 and 5 localization will be analyzed. Aim II will be achieved through chromatin immunoprecipitation of YY1 and the various fetal gene promoters in response to hypertrophic stimuli. Aim IV will be achieved by creating a conditional transgenic mouse model of YY1 over-expression. Hypertrophy will be induced in these animals by implantation of mini-osmotic pumps containing hypertrophic agonists, and heart function and changes in cellular hypertrophy will be analyzed. The data revealed from these studies will rapidly progress our understanding of the signaling components responsible for the development of pathologic cardiac hypertrophy.
描述(由申请人提供):心力衰竭是美国最昂贵的医疗问题,也是死亡和残疾的主要原因。尽管靶向治疗心力衰竭的药理学抑制剂在治疗上是有益的,但心力衰竭的频率仍在增加,并且需要额外的靶点。我们的长期目标是确定转录因子YY 1保护病理性心脏肥大的分子机制,并为预防心脏疾病提供有价值的靶点。YY 1是一种普遍存在的转录因子,调节多个基因的表达。YY 1已被证明主要是肌肉基因的阻遏物。我们有强有力的初步数据表明,YY 1可以防止伴随心脏肥大的细胞变化。YY 1通过结合并保留在细胞核中的II类组蛋白脱乙酰酶(HDAC)来防止响应于α和β肾上腺素能刺激的基因表达的胎儿同种型的上调。本申请的目的是:(目的I)鉴定YY 1响应于各种肥大激动剂而阻止HDAC 4和5核输出的机制;(目的II)分析YY 1响应于各种肥大刺激而与胎儿基因启动子的相互作用(目的III)表征YY 1过表达在病理性心脏肥大的体内模型系统中的作用。目的通过分析YY 1-HDAC相互作用结构域实现I;将含有相互作用结构域的构建体转染到新生心肌细胞中,并分析基因表达、细胞肥大和HDAC 4和5定位。目的II将通过染色质免疫沉淀YY 1和各种胎儿基因启动子响应肥大刺激。目的IV通过建立YY 1过表达的条件性转基因小鼠模型来实现。通过植入含有肥大激动剂的微型渗透泵诱导这些动物的肥大,并分析心脏功能和细胞肥大的变化。这些研究揭示的数据将迅速推进我们对病理性心脏肥大发展的信号传导成分的理解。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CARMEN C SUCHAROV其他文献
CARMEN C SUCHAROV的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CARMEN C SUCHAROV', 18)}}的其他基金
Investigations of Pathologic Remodeling Using Pediatric Heart Failure Serum
使用小儿心力衰竭血清进行病理重塑的研究
- 批准号:
10548138 - 财政年份:2019
- 资助金额:
$ 12.18万 - 项目类别:
Investigations of Pathologic Remodeling Using Pediatric Heart Failure Serum
使用小儿心力衰竭血清进行病理重塑的研究
- 批准号:
10312788 - 财政年份:2019
- 资助金额:
$ 12.18万 - 项目类别:
Investigations of Pathologic Remodeling Using Pediatric Heart Failure Serum
使用小儿心力衰竭血清进行病理重塑的研究
- 批准号:
10064022 - 财政年份:2019
- 资助金额:
$ 12.18万 - 项目类别:
Non-invasive risk assessment tool for pediatric heart failure
小儿心力衰竭的无创风险评估工具
- 批准号:
9410210 - 财政年份:2017
- 资助金额:
$ 12.18万 - 项目类别:
Mechanisms of YY1 Inhibition of Cardiac Hypertrophy
YY1抑制心肌肥厚的机制
- 批准号:
7796890 - 财政年份:2007
- 资助金额:
$ 12.18万 - 项目类别:
Mechanisms of YY1 Inhibition of Cardiac Hypertrophy
YY1抑制心肌肥厚的机制
- 批准号:
7405359 - 财政年份:2007
- 资助金额:
$ 12.18万 - 项目类别:
Mechanisms of YY1 Inhibition of Cardiac Hypertrophy
YY1抑制心肌肥厚的机制
- 批准号:
7655433 - 财政年份:2007
- 资助金额:
$ 12.18万 - 项目类别:
Mechanisms of YY1 Inhibition of Cardiac Hypertrophy
YY1抑制心肌肥厚的机制
- 批准号:
8051620 - 财政年份:2007
- 资助金额:
$ 12.18万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 12.18万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 12.18万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 12.18万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 12.18万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 12.18万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 12.18万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 12.18万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 12.18万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 12.18万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 12.18万 - 项目类别: